Objectives

We aimed to determine adverse reactions and influencing factors, within the scope of the number of patients and total infusions, in patients with primary immunodeficiencies receiving intravenous immunoglobulin (IVIG) replacement.

Materials and methods

Children with primary immunodeficiencies receiving IVIG replacement in Izmir Dr Behcet Uz Children’s Hospital, between June 2014 and June 2016, were included in our study.

Results

The total number of the patients receiving IVIG replacement was 145 (37 female, 108 male). The number of total IVIG infusions was 1214. Adverse reactions were observed in 44.8% of the patients and 14.2% of the infusions. Common variable immunodeficiency was the most common diagnosis of the patients and adverse reactions most commonly developed in this group (24.2%). In all infusions the most frequent adverse reaction was headache (7.8%); fever was the most frequent immediate side effect (3.9%), whereas headache was the most common delayed adverse effect (5.1%). By logistic regression analyses, history of adverse reaction to IVIG in previous infusions, existence of concomitant infectious disease, past or family history of atopic disease, to receive IVIG infusion at the first time, or being under 10 years old were found associated with adverse reactions. There was no correlation between the concentration of IVIG preparations and the rate of side-effect development.

Conclusions

In our study no severe adverse reaction to IVIG was observed, but many mild or moderate side effects occurred. Therefore, IVIG indications must be well identified. Patients, family of the patients and health care workers must be informed for adverse reactions.

中文翻译：

---

原发性免疫缺陷患儿接受静脉免疫球蛋白替代治疗的不良反应及影响因素[J].

目标

我们旨在确定接受静脉注射免疫球蛋白（IVIG）替代治疗的原发性免疫缺陷患者在患者人数和总输注量范围内的不良反应和影响因素。

材料和方法

我们的研究包括了 2014 年 6 月至 2016 年 6 月在伊兹密尔 Dr Behcet Uz 儿童医院接受 IVIG 替代治疗的原发性免疫缺陷儿童。

结果

接受 IVIG 替代治疗的患者总数为 145 人（女性 37 人，男性 108 人）。IVIG总输注次数为1214次。在44.8%的患者和14.2%的输注中观察到不良反应。常见变量免疫缺陷是患者最常见的诊断，不良反应在该组中最常见（24.2%）。在所有输注中，最常见的不良反应是头痛（7.8%）；发热是最常见的即刻副作用（3.9%），而头痛是最常见的延迟性副作用（5.1%）。通过logistic回归分析，既往输注IVIG不良反应史，存在合并感染性疾病，特应性疾病既往史或家族史，首次接受IVIG输注，或未满 10 岁被发现与不良反应有关。IVIG 制剂的浓度与副作用发生率之间没有相关性。

结论

在我们的研究中，没有观察到 IVIG 的严重不良反应，但发生了许多轻度或中度的副作用。因此，必须很好地识别IVIG适应症。必须将不良反应告知患者、患者家属和医护人员。